Press monitoring
Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
5.11.2015 | Press monitoring
Paris, France and Seoul, Korea - Nov. 5, 2015 - Sanofi and Hanmi Pharmaceutical Co., Ltd. announced today a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
5.11.2015 | Press monitoring
PHILADELPHIA and OXFORD, UK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents updated data on its lead clinical program, an affinity enhanced T-cell receptor therapy targeting the NY-ESO-1 cancer antigen in synovial sarcoma, at the...
Singulex Receives European Patent Expanding Use of Biomarkers Troponin I and T to Detect Cardiac Health Status With High-Sensitivity Methods
5.11.2015 | Press monitoring
ALAMEDA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) - Singulex, Inc. , the developer of Single Molecule Counting technology for use in both medical practice diagnostics and scientific research, has received from the European Patent Office (EPO) a key patent (EP2002260) for use of the biomarkers troponin I and T to detect cardiac damage in humans using...
Sanofi and the Institut Pasteur reward four researchers for their major contributions in the service of health
4.11.2015 | Press monitoring
Paris, France - November 4 th 2015 - Sanofi and the Institut Pasteur have attributed today the Sanofi - Institut Pasteur Awards for the fourth year in a row. Four major researchers with international recognition have been rewarded for their works in two major fields for global health: tropical and neglected diseases and immunolog...
Study uses gene editing to take brakes off lab-based red blood cell production
4.11.2015 | Press monitoring
Turning off a single gene leads to a roughly three-to-five-fold gain in the yield of laboratory methods for producing red blood cells from stem cells, according to a multi-institutional team led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. These findings, published in Cell Stem Cell, suggest a way to...
Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement
3.11.2015 | Press monitoring
Paris, France and Mainz, Germany - November 3, 2015 - Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer...
Drug could kill mosquitoes when they feast on human blood
2.11.2015 | Press monitoring
Ivermectin, the 30-year-old antiparasitic drug whose discovery was honored with a Nobel Prize last month, may have another trick up its sleeve: killing mosquitoes. A new study in Burkina Faso suggests that mass-administering ivermectin to people may kill or weaken the mosquitoes feeding on them, and thus make a dent in malaria t...
MorphoSys Announces Clinical Milestone in Hemophilia Program with Bayer HealthCare
30.10.2015 | Press monitoring
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has received a milestone payment from Bayer HealthCare in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of bleeding disorders. The antibody targets the tissue factor pathway inhibitor (TFPI), a major inhibitor...
First cancer-fighting virus approved
30.10.2015 | Press monitoring
US regulators clear a viral melanoma therapy, paving the way for a promising field with a chequered past. An engineered herpesvirus that provokes an immune response against cancer has become the first treatment of its kind to be approved for use in the United States, paving the way for a long-awaited class of therapies. On 27 October, the US Food...
Novartis Foundation and partners launch new hypertension program in Ghana
29.10.2015 | Press monitoring
Basel, October 29, 2015 - The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana.
